Shufeng Xingbi Therapy in Allergic Rhinitis Rats

Allergic rhinitis is commonly studied as a localized nasal inflammatory disorder, but increasing evidence connects airway allergy with intestinal microbial composition and microbial metabolites. The reference study, a bioRxiv preprint posted in 2025 and not certified by peer review, investigates this connection through a rat model of allergic rhinitis (AR). The authors test Shufeng Xingbi Therapy (SFXBT), consisting of an orally administered Shufeng Xingbi formulation combined with externally applied Xingbi gel nasal drops, and assess whether treatment is associated with changes in immune balance and gut ecology. The full study is available through the reference preprint.

Study Background and Research Question

AR is characterized by symptoms such as paroxysmal sneezing, watery discharge, itching, and congestion. IgE-associated inflammation and an imbalance between T helper 1 and T helper 2 responses are central to the conventional immunological framework. The authors place this biology alongside the hygiene hypothesis and the possibility that intestinal microorganisms influence allergic inflammation through metabolites such as short-chain fatty acids (SCFAs).

The research question is therefore broader than whether SFXBT reduces nasal symptoms. It asks whether the intervention is linked to coordinated changes in nasal mucosal signaling, serum IgE and interleukin-4 (IL-4), colonic bacterial composition, and SCFA concentrations. This framing is important because it treats the gut and nasal mucosa as connected components of an experimental immune axis rather than evaluating the therapy only by behavioral scores. The rationale and stated objectives are described in the study report.

Key Innovation from the Reference Study

The study’s principal innovation is its multi-layered design. Many AR experiments focus on symptoms, histology, or a small number of cytokines. Here, the authors combine four evidence streams: clinical-like behavioral scoring, hematoxylin and eosin staining of nasal mucosa, immune and signaling assays, and intestinal microbiome profiling. The addition of SCFAs provides a metabolic readout that may help connect bacterial shifts with host immune activity.

A second notable feature is the comparison of two intervention-associated groups: an antibiotic plus SFXBT group and an acetic acid plus SFXBT group. These groups were evaluated alongside an untreated control and an ovalbumin (OVA) model group. This arrangement appears intended to examine therapy under different microbial or metabolic contexts, although the condensed report does not establish that either manipulation selectively changes one defined pathway. The design is consequently hypothesis-generating rather than a definitive demonstration that gut bacteria or SCFAs mediate the nasal response.

Methods and Experimental Design Insights

The investigators used 32 clean, healthy male Sprague–Dawley rats. The animals were six weeks old and weighed 200–250 g at enrollment, according to the reference study. Rats were randomly assigned to four groups: control, OVA, antibiotic plus SFXBT, and acetic acid plus SFXBT. The OVA group served as the allergic rhinitis model comparator, allowing treatment-associated changes to be interpreted against allergen-induced pathology rather than against healthy animals alone.

The outcome panel was deliberately broad. AR behavioral scores provided a functional measure of sneezing or related nasal responses, while H&E staining was used to examine tissue-level changes in the nasal mucosa. Serum IgE and IL-4 were measured by ELISA. Colonic contents were analyzed using 16S rDNA sequencing to estimate bacterial community composition, and serum SCFAs were also assessed by ELISA according to the condensed methods. At the molecular level, reverse-transcription quantitative PCR measured STAT5, STAT6, and GATA3 messenger RNA in nasal mucosa; Western blotting measured IL-4, STAT5, STAT6, and GATA3 proteins.

This combination creates useful biological triangulation. A lower behavioral score is more persuasive when it occurs alongside improved histology, reduced allergic markers, and altered transcriptional or protein signals. However, the design still mainly measures associations. 16S rDNA sequencing describes relative community structure rather than absolute bacterial numbers, and the reported measurements do not by themselves prove that a specific genus produces the observed SCFA changes or directly controls nasal STAT/GATA3 signaling.

Protocol Parameters

• Animal model: Use the OVA-induced allergic rhinitis framework described in the full preprint; the supplied summary does not provide complete sensitization and challenge doses or timing.
• Experimental groups: Randomize 32 male Sprague–Dawley rats into control, OVA, antibiotic plus SFXBT, and acetic acid plus SFXBT groups, with group sizes and allocation details verified against the full methods.
• Therapy format: Interpret SFXBT as the combined oral Shufeng Xingbi formulation and external Xingbi gel nasal administration reported by the authors; do not infer dosing schedules that are absent from the condensed record.
• Primary phenotyping: Pair AR behavioral scoring with nasal mucosal H&E examination to distinguish symptom changes from structural inflammatory changes.
• Mechanistic readouts: Combine serum IgE, IL-4, and SCFAs with 16S rDNA sequencing, RT-qPCR, and Western blotting so microbiome, metabolite, transcript, and protein results can be compared within the same experiment.

Core Findings and Why They Matter

Relative to the OVA model group, both the antibiotic plus SFXBT and acetic acid plus SFXBT groups showed lower AR behavioral scores, with the reported difference reaching P < 0.01. Nasal mucosal pathological changes were also alleviated. These findings support an anti-inflammatory association for SFXBT in this model, although they do not separate the effect of SFXBT from the effects of the antibiotic or acetic acid co-interventions.

The microbiome analysis identified shifts at both phylum and genus levels. Firmicutes increased in relative abundance, whereas Bacteroidetes decreased. At the genus level, Lactobacillus, Romboutsia, Allobaculum, and Dubosiella increased significantly in fecal samples. Such changes are relevant because they suggest that the intervention may alter the intestinal community in parallel with improvements in nasal inflammation. Nevertheless, relative-abundance changes should not be interpreted as proof of improved microbial function without absolute quantification, metagenomic or metatranscriptomic data, and direct metabolite attribution.

Serum IgE and IL-4 decreased, while SCFA concentrations increased, with reported significance at P < 0.05. In nasal tissue, STAT5, STAT6, and GATA3 mRNA and protein expression also decreased significantly. These results are consistent with attenuation of a Th2-associated allergic response, particularly given the reduction in IL-4 and GATA3-related signaling. The title’s reference to Th1/Th2 balance should therefore be interpreted cautiously: the reported marker set emphasizes Th2-associated pathways, and the condensed findings do not describe a complete panel of Th1 cytokines or a direct ratio-based assessment.

The meaningful advance is the convergence of these observations. Behavioral improvement, tissue recovery, lower allergic mediators, increased SCFAs, and altered bacterial profiles form a coherent hypothesis that SFXBT may influence AR through a gut–immune connection. The evidence remains mechanistic groundwork rather than proof of a microbiota-dependent pathway, but it gives future studies specific variables to test.

Comparison with Existing Internal Articles

The microbiome–immune interpretation can be compared with the internal article L. acidophilus–UDCA Mechanisms in Ulcerative Colitis. That work describes a microbiota-dependent pathway involving Lactobacillus acidophilus, ursodeoxycholic acid, regulatory T-cell differentiation, M1 macrophage polarization, and RapGap/PI3K-AKT/NF-κB signaling in experimental colitis. The AR preprint also reports increased Lactobacillus and links microbial change with an immune phenotype, but it does not measure UDCA, regulatory T cells, macrophage polarization, or the signaling pathway emphasized in the colitis study.

The relationship is therefore conceptual rather than confirmatory. Both studies support examining microbial metabolites as immune-regulatory intermediates, while the AR work contributes nasal mucosal STAT5, STAT6, and GATA3 measurements instead of the colitis-focused endpoints. Cross-disease comparisons should not be treated as evidence that the same metabolite or cell population mediates both phenotypes.

Limitations and Transferability

Several limitations affect interpretation. First, the report is a preprint and has not undergone peer review. Second, the sample is small and restricted to young male rats, limiting generalization across sex, age, strain, and disease severity. Third, the antibiotic and acetic acid groups introduce additional biological perturbations. Because each is paired with SFXBT rather than with a matched antibiotic-only or acetic-acid-only control, the experiment cannot determine whether observed changes arise from SFXBT, the co-intervention, or their interaction.

Fourth, 16S profiling provides taxonomic association but limited functional resolution. Increased relative abundance of a genus does not establish increased activity, SCFA production, or causal influence on nasal immunity. Fecal measurements also may not represent mucosal microbial communities. Fifth, reduced STAT5, STAT6, and GATA3 expression is compatible with altered allergic signaling but is not sufficient to demonstrate restoration of a balanced Th1/Th2 ratio. Future studies would benefit from factorial controls, larger and more diverse cohorts, longitudinal sampling, absolute microbial quantification, broader cytokine panels, and intervention experiments that directly test whether SCFA changes are necessary for the nasal effect.

Transfer to human AR should consequently be conservative. The findings provide a rationale for investigating gut–nasal immune interactions, but they do not establish clinical efficacy, an optimal dose, or safety in patients. They also do not show that a particular bacterial genus is a therapeutic target.

Research Support Resources

Why this cross-domain matters, maturity, and limitations

For adjacent molecular assays, researchers can use Neomycin sulfate (SKU B1795), an aminoglycoside antibiotic, in RNA/DNA structure interaction studies. The product information describes DNA triplex structure stabilization and use as a ryanodine receptor channel blocker, but these are assay-specific applications and are not interventions tested in the AR rat study. Accordingly, this reagent should support mechanistic molecular biology workflows rather than be presented as a substitute for SFXBT or as evidence-based treatment for allergic rhinitis.